Sign in Subscribe
Drugs

Tamoxifen Discontinuation Linked to CYP2D6 Polymorphisms

Strategic Insights

— 1 min read

Breast cancer patients are often prescribed tamoxifen, a selective estrogen receptor modulator, for treatment and prevention of estrogen-receptor-positive breast cancer. However, studies have shown that over half of these patients discontinue treatment before the recommended 5 years. Researchers from the University of Michigan have found a strong correlation between CYP2D6 polymorphisms and tamoxifen discontinuation. In their study, published in the Pharmacogenomics Journal in 2009, J.M. Rae and colleagues analyzed the genetic profiles of 297 tamoxifen-treated women and found that those with active CYP2D6 alleles were more likely to discontinue treatment prematurely.

Key Takeaways:

  • Over 50% of patients discontinue tamoxifen treatment before the recommended 5 years, according to studies.
  • CYP2D6 polymorphisms predict tamoxifen discontinuation, with a strong nonlinear correlation between CYP2D6 score and increased rates of discontinuation.
  • Patients with active CYP2D6 alleles may be more likely to discontinue tamoxifen treatment, despite potentially benefiting from the therapy.
  • The study suggests that pharmacogenomics could play a crucial role in identifying patients at risk of tamoxifen discontinuation.
  • The study was conducted by J.M. Rae and colleagues at the University of Michigan, Department of Internal Medicine.
  • The study's findings have important implications for personalized medicine and the development of targeted therapies.

Statistics:

  • 297 patients were genotyped for CYP2D6 variants in the study.
  • The correlation between CYP2D6 score and discontinuation rates at 4 months was strong, with an r(2) value of 0.935 and a P-value of 0.018.
  • The study found a nonlinear relationship between CYP2D6 score and increased rates of discontinuation.
  • Approximately 50% or more of patients discontinue tamoxifen treatment before the recommended 5 years.

Sources:

  • Rae, J.M., et al. (2009). Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Pharmacogenomics Journal, 9(4), 258-264. doi: 10.1038/tpj.2009.14
  • Retrieved from Nature Publishing Group, Macmillan Building, 4 Crinan St., London N1 9XW, England.

Read more